SCHEMBL1874241

SCHEMBL1874241

CC(C)(C)OC(=O)N(OC(C)(C)C)c1nccc(-c2c(-c3ccc(Cl)cc3)noc2N)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPT P10636 3/20 0.38
NPSR1 Q6W5P4 2/20 0.38
MAPK14 Q16539 3/20 0.37
MAPK9 P45984 1/20 0.37
MAPK10 P53779 1/20 0.37
MAPK11 Q15759 1/20 0.37
CYP3A4 P08684 1/20 0.33
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA4 P22748 1/20 0.32
CA7 P43166 1/20 0.32
PIM1 P11309 1/20 0.32
MAP4K4 O95819 1/20 0.32
MLYCD O95822 1/20 0.32
GPBAR1 Q8TDU6 1/20 0.32
KMO O15229 1/20 0.32
CNR2 P34972 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1872632 0.81 MAPK14 (0.36) POLBTDP1L3MBTL1MAPTNPSR1
SCHEMBL1875148 0.80 MAPK14 (0.51) MAPTNPSR1MAPK14MAPK9MAPK10
SCHEMBL1878387 0.80 MAPK14 (0.63) MAPTNPSR1MAPK14MAPK9MAPK10
SCHEMBL1875402 0.79 EGFR (0.38) MAPK14MAPK10CYP3A4
SCHEMBL1874168 0.77 MAPK14 (0.45) MAPTMAPK14MAPK9MAPK10MAPK11
SCHEMBL1881585 0.69 MAPK14 (0.56) MAPK14MAPK9MAPK10MAPK11
SCHEMBL1881783 0.68 SSTR4 (0.35)
SCHEMBL1875304 0.68 MAPK14 (0.57) MAPTMAPK14MAPK9MAPK10MAPK11
SCHEMBL1876999 0.67 MAPK14 (0.75) POLBTDP1L3MBTL1MAPTMAPK14
SCHEMBL25351827 0.64 MAPK14 (0.58) POLBTDP1L3MBTL1MAPTMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1832584-B1 PYRIMIDINYLISOXAZOLE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-12-21 EP disclosed
US-7939536-B2 5-[(2-chlorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole; p 38MAP kinase inhibitor; tumor necrosis factor, interleukin, or cyclooxygenase-II related diseases; antiinflammatory, anticarcinogenic, antidiabetic agent ASKA PHARMACEUTICAL CO., LTD. (JP) 2011-05-10 US disclosed
US-20080114003-A1 Pyrimidinylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-15 US disclosed
EP-1832584-A1 PYRIMIDINYLISOXAZOL DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114003-A1 Pyrimidinylisoxazole Derivatives MAPK3, MAPK7, MAP3K7 POLB 3499/4885TDP1 2279/4885L3MBTL1 1032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.